Peter Hovland, MD
Ophthalmology · Denver, CONPI 1720047210
Payments from drug & device makers
What this record shows
The money is spread across several categories — ownership interests (50.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by US Retina LLC at 50.9% of the total. Reporting peaked in 2019 at $2,490 and has fallen 71.9% since, to $701 in 2025. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $91.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$5K
- Alcon$1K
- AbbVie$956
- Regeneron Healthcare Solutions, Inc.$813
- Genentech, Inc.$782
- Genentech USA, Inc.$433
- plus $969 from 13 others
Across 43 payments — averaging $12,963 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$557K
What the payments were for
- Grants$831%
- Travel & lodging$6366%
- Food & beverage$3,49935%
- Education$7507%
- Ownership interest$5,14351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 4 | $5,143 |
| Alcon | 5 | $1,015 |
| AbbVie(2 entities) | 11 | $956 |
| Regeneron Healthcare Solutions, Inc. | 27 | $813 |
| Genentech, Inc. | 6 | $782 |
| Genentech USA, Inc. | 16 | $433 |
| Novartis | 10 | $286 |
| Astellas Pharma US Inc | 8 | $177 |
| Biogen | 8 | $145 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $96 |
| Bausch & Lomb Americas Inc. | 3 | $65 |
| Neurotech Pharmaceuticals, Inc. | 2 | $56 |
| Coherus Oncology, Inc. | 2 | $32 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Stryker | 1 | $22 |
| Eyepoint US, Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Topcon Healthcare Solutions, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,111 in reported general payments places this provider in the 90th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 53 | $2,043 |
| Difluprednate | 12 | $1,864 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 66 | $839 |
| Ketorolac Tromethamine | 17 | $532 |
| Acetazolamide | 11 | $446 |
| Dorzolamide Hcl | 22 | $431 |
| Timolol Maleate | 22 | $261 |
| Latanoprost | 16 | $195 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Denver
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
- Kingsley OkaforDenver$62K
- Curtis HagedornDenver$25K
- Michael SolomonDenver$12K
- Matthew KrugerDenver$8K
- Stuart LewisDenver$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.